Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Disease Progression
Female
Follow-Up Studies
Humans
Immunotherapy
/ methods
Male
Middle Aged
Neoplasm Metastasis
Neoplastic Cells, Circulating
/ pathology
Prognosis
Retrospective Studies
Survival Rate
T-Lymphocytes
/ classification
Urogenital Neoplasms
/ immunology
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
27
07
2020
revised:
13
10
2020
accepted:
25
11
2020
pubmed:
3
12
2020
medline:
11
2
2022
entrez:
2
12
2020
Statut:
ppublish
Résumé
Circulating tumor cells (CTC) are under investigation as a minimally invasive liquid biopsy that may improve risk stratification and treatment selection. CTCs uniquely allow for digital pathology of individual malignant cell morphology and marker expression. We compared CTC features and T-cell counts with survival endpoints in a cohort of patients with metastatic genitourinary cancer treated with combination immunotherapy. Markers evaluated included pan-CK/CD45/PD-L1/DAPI for CTCs and CD4/CD8/Ki-67/DAPI for T cells. ANOVA was used to compare CTC burden and T-cell populations across timepoints. Differences in survival and disease progression were evaluated using the maximum log-rank test. From December 2016 to January 2019, 183 samples from 81 patients were tested. CTCs were found in 75% of patients at baseline. CTC burden was associated with shorter overall survival (OS) at baseline ( Shorter survival may be associated with high CTC counts at baseline, presence of specific CTC morphologic subtypes, PD-L1
Identifiants
pubmed: 33262136
pii: 1078-0432.CCR-20-2891
doi: 10.1158/1078-0432.CCR-20-2891
pmc: PMC7925349
mid: NIHMS1651263
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1391-1398Subventions
Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186712
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011928
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011351
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011594
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Eur Urol. 2020 Feb;77(2):170-177
pubmed: 31648903
J Biomed Opt. 2019 Aug;24(8):1-4
pubmed: 31432656
Br J Cancer. 2015 Oct 20;113(8):1225-33
pubmed: 26379078
Cell Mol Life Sci. 2018 Feb;75(4):689-713
pubmed: 29032503
J Circ Biomark. 2015 May 5;4:3
pubmed: 28936239
Phys Biol. 2012 Feb;9(1):016003
pubmed: 22306768
J Oncol. 2010;2010:861341
pubmed: 20111743
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Clin Cancer Res. 2016 Mar 15;22(6):1510-9
pubmed: 26671992
Eur Urol Focus. 2016 Feb;1(3):269-271
pubmed: 28723398
Eur Urol Oncol. 2021 Apr;4(2):310-314
pubmed: 31563523
Clin Cancer Res. 2019 Dec 1;25(23):6909-6915
pubmed: 31285372
J Clin Oncol. 2020 Nov 1;38(31):3672-3684
pubmed: 32915679
Lancet Oncol. 2020 Aug;21(8):1099-1109
pubmed: 32645282
JAMA Oncol. 2016 Nov 01;2(11):1441-1449
pubmed: 27262168
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1139-1145
pubmed: 28446544
BMC Cancer. 2016 Sep 22;16(1):744
pubmed: 27658492
Cancer Res. 2017 Oct 15;77(20):5687-5698
pubmed: 28819021
Oncotarget. 2018 Jun 19;9(47):28561-28571
pubmed: 29983880
Oncotarget. 2017 Jun 16;8(35):59527-59538
pubmed: 28938656
Oncotarget. 2016 Sep 20;7(38):62754-62766
pubmed: 27517159